PreTT is transforming cancer treatment with advanced pretargeted radioligand therapies that surpass traditional methods. Our proprietary technology enhances radioimmunotherapy, using monoclonal antibodies (mAbs) for precise targeting of cancer cells while sparing healthy tissue.